Conference report: Updated CHECKMATE-025 phase III trial shows improved 5-year overall survival with nivolumab vs everolimus

At 64 months, 26% of patients on nivolumab vs 18% on everolimus were alive, and percentage of patients experiencing an objective response was 23% vs 4% respectively.

Source:

Biospace Inc.